Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

CRISPR Therapeutics AG. (11/28/17). "Press Release: CRISPR Therapeutics to Participate in Upcoming Investor Conferences". Zug & Cambridge, MA.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Piper Jaffray & Co. (NYSE: PJC)
  Group Piper Jaffray (Group)
Products Product Barclays Gene Editing & Gene Therapy Summit 2017 New York
  Product 2 Evercore ISI BioPharma Catalyst / Deep Dive Conference 2017 Boston
Index terms Index term CRISPR Therapeutics–Piper Jaffray: investor conference, 201711 supply service CRISPR Therapeutics at Piper Jaffray Healthcare Conference 2017
  Index term 2 CRISPR Therapeutics–Citigroup: investor conference, 201712 supply service 1-on-1 meetings at Citi Global Healthcare Conference NY
Persons Person Paganelli, Jennifer (W2O Group 201703)
  Person 2 Brinzey, Chris (Westwicke Partners 201703)
     


CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present or host one-on-one meetings at five upcoming Investor Conferences.

29th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 29, 2017
Fireside Chat: 1:00-1:25 PM ET

Barclays Gene Editing & Gene Therapy Summit
Date: Thursday, November 30, 2017
Presentation: 3:00-3:20 PM ET
Panel Discussion: 3:40-4:40 PM ET Gene Editing: Putting Molecular Scissors in Real Life Use

Evercore ISI BioPharma Catalyst/Deep Dive Conference
Date: Thursday, November 30, 2017
Fireside Chat: 10:15-10:35 AM ET

Citi 2017 Global Healthcare Conference
Date: Wednesday December 6, 2017
One-on-one meetings only

Guggenheim 4th Annual Boston Healthcare Conference
Date: Tuesday December 13, 2017
One-on-one meetings only


About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.


MEDIA CONTACTS:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:
Chris Erdman
+1 617.307.7227 chris.erdman@crisprtx.com

Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 chris.brinzey@westwicke.com

   
Record changed: 2017-12-11

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top